Vascular Sensitivity to Adrenergic Agonists in Patients With CHF and in Healthy Subjects
Effect of Medications on Vascular Response in Patients With CHF and in Healthy Subjects
1 other identifier
observational
80
1 country
1
Brief Summary
Congestive Heart failure (CHF) is asociated with changes in cardiac function and vascular responses. The aim of this study is to characterize these differences. Our hypothesis is, that there are differences in vascular responses between healthy subjects and patients with CHF.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2008
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2008
CompletedFirst Submitted
Initial submission to the registry
October 26, 2008
CompletedFirst Posted
Study publicly available on registry
October 31, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2011
CompletedOctober 31, 2008
October 1, 2008
1.3 years
October 26, 2008
October 28, 2008
Conditions
Outcome Measures
Primary Outcomes (1)
vascular sensitivity (ED50) and response (Emax) to dexmedetomidine, phenylephrine, isoproterenol and terbutaline
3 weeks
Eligibility Criteria
Patients with congestive heart failure NYHA I-II and healthy subjects
You may qualify if:
- Patients with congestive heart failure NYHA I-II
- Stable clinical condition
You may not qualify if:
- Resting systolic blood pressure \< 100
- Resting heart rate \< 50
- Hypersensitivity to dexmedetomidine, phenylephrine, isoproterenol, terbutaline
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hadassah University Hospital
Jerusalem, 92110, Israel
Biospecimen
samples for norepinephrine and PRA will be retained
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mordechai Muszkat
Hadassah University Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
October 26, 2008
First Posted
October 31, 2008
Study Start
August 1, 2008
Primary Completion
December 1, 2009
Study Completion
December 1, 2011
Last Updated
October 31, 2008
Record last verified: 2008-10